Sana Biotechnology announced an abstract highlighting preclinical nonhuman primate data for SG293 has been accepted for oral presentation at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston, taking place 11-15 May 2026, with the SG293 presentation scheduled for 12 May 2026 at 8:15 a.m. ET during the session, advancing in vivo gene delivery with non-AAV viral vector systems.
The presentation is titled Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293 and is listed as Abstract Number 20.
According to the company, SG293 uses Sana’s proprietary fusogen-based delivery technology and is a CD8-targeted fusosome designed to deliver the genetic material to create CD19-directed CAR T cells while avoiding delivery to tissues such as the liver. The company claims it intends to explore SG293 in both B-cell cancers and B-cell-mediated autoimmune diseases.
